invIOs is teaming up with the Medical University of Innsbruck on a new project to investigate the potential of an innovative CAR-T cell therapy approach to treat aggressive lung tumors....

We were privileged to welcome Professor Christoph Zielinski as our latest speaker in the invIOs Innovation Lectures. One of Europe's most distinguished medical oncologists, Professor Zielinski shared with us insights...

Clinical trials are crucial to understanding how drugs and therapies work, how safe they are in humans, and how effective they are in treating cancer. They are vital for making...

Although cancer represents a huge challenge for our healthcare systems, new immunotherapies and other advanced novel treatments mean hope is on the horizon. Cancer is one of the all-pervading topics...

1. Do cell therapies represent a breakthrough in cancer treatment? Mario Kuttke: It is really amazing how adoptive cell therapy (ACT), a form of cancer immunotherapy, has evolved so rapidly...

invIOs’s novel clinical stage lead therapeutic candidate, APN401, combines advances in immune cell therapy and RNA interference methods to treat advanced solid cancers. Immune therapy – hitting new targets Immune...

1. Ribonucleic acids have for a long time been DNA’s “little sister”. What’s so different between RNA and DNA? Alexander Dohnal: RNA and DNA have a lot in common. Chemical...

Ribonucleic acid (RNA) therapies are promising to change the way we treat diseases. From cancer therapies to vaccines and treatments for genetic diseases, the opportunities are almost infinite.